At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 10, 2026 at 16:01 ET
vTv Therapeutics reported Q4 and full-year 2025 financial results, highlighted by a significant cash increase to $88.9 million from an $80 million financing and a $20 million upfront payment from Newsoara under an amended licensing deal. The company expects to complete enrollment in its Phase 3 CATT1 trial for cadisegliatin in Q3 2026, with a funding runway extending beyond the topline readout. However, net losses widened year-over-year due to higher R&D and G&A expenses.
- Received $20.0 million upfront from Newsoara in February 2026 under an amended licensing agreement for global rights to PDE4 inhibitor HPP737.
- Cash position was $88.9 million as of December 31, 2025, up from $36.7 million a year prior, driven by $80 million private placement and licensing proceeds.
- Net loss for Q4 2025 was $7.1 million vs. $3.6 million in Q4 2024; full-year 2025 net loss was $27.0 million vs. $18.5 million in 2024.
- R&D expenses increased to $17.9 million in 2025 from $11.5 million in 2024, primarily due to cadisegliatin clinical trials.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access